49 participants
Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-08-24
- Start Date:
- 2022-03-21
- Completion:
- 2027-03-31
Conditions
- Relapsed Mantle Cell Lymphoma
- Refractory Mantle Cell Lymphoma
Interventions
- DRUG
No Results Yet